Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of BYETTA is substantial. |
Clinical Added Value
| minor |
BYETTA provides a minor improvement in actual benefit (IAB IV) in the management of type-2 diabetes in patients treated with a combination of metformin and hypoglycaemic sulphonylurea who have not achieved adequate blood glucose control at the highest tolerated doses of these treatments. |
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
hGxTUPGb32VBNPmj
